ClinicaliQ Trial Snapshot
- A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes — Active Not Recruiting • Phase I / Phase II • Diabetes / Metabolic • NCT05791201.
- VX-264 trial tested a new drug's safety and effectiveness in type 1 diabetes patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D). Conditions: Type 1 Diabetes Interventions: VX-264 Lead Sponsor: Vertex Pharmaceuticals Incorporated Planned Enrollment: 7 participants